Interestingly in the present study, IL1B was more highly expressed in VS than meningioma and therefore drugs such as anakinra and canakinumab, previously suggested as a potential treatment for VS-induced sensorineural hearing loss, [16] may be effective for hearing loss and VS treatment without contraindications in meningioma. This evidence concerns the gene IL1B and meningioma.